On February 6, GSK reported its 2018 results, with annual revenue of 308.£2.1 billion (409.$9.2 billion), up 5% from 2017.Pharmaceutical business income is £17.3 billion (+ 2%), vaccine business income is £5.9 billion (+ 16%), and consumer health care business income is £7.7 billion (+ 2%); GSK R & D investment in 2018 is 38.£9.3 billion (51.$7.8 billion), accounting for a proportion of revenue 12.6%, down 13% from 2017.
GSK's current dominant business focuses on respiratory diseases.AIDS and vaccines in three major areas.
Overall sales of Ellipta family products increased by 32.3%, reaching $2.725 billion. Nucala is the world's first marketed IL-5 monoclonal antibody for the treatment of eosinophilic refractory asthma, with approval in more countries, Nucala Sales reached $ 749 million in the third year of listing. These new products compensated Seretide's impact on the patent cliff and maintained the growth of the entire respiratory business.
In the AIDS business, 11% growth was achieved led by the dolutegravir series, with overall revenue reaching $6.187 billion. Gilead’s AIDS business was approximately $15 billion.
In terms of vaccines, the shingle vaccine Shingrix was approved by Canada and the United States in October 2017, followed by the CDC recommended by the US CDC for over 50 years old. The sales revenue in 2018 directly exceeded 1 billion US dollars, driving the entire vaccine market of GSK. 16%, and successfully grabbed 98% of the US market, and sales of Merck's old product Zostavax directly from $668 million in 2017 to $217 million. GSK and Merck's another set of tit-for-tat vaccine products It is the cervical cancer vaccine Cervarix and Gardasil 9, the reality is also the opposite.Gardasil 9 has been looted in China and its supply is extremely tight, with global revenues soaring 37% to $3.1 billion in 2018.84亿美元（+5%）.
GSK underwent a major business adjustment in 2014, replacing Novartis's vaccine business assets (excluding Novartis's flu vaccine) with its entire on-campus business assets, and establishing a joint venture with Novartis focused on consumer health, with GSK accounting for 63%. 5%. After the burden reduction, GSK has indeed returned to the growth track under the strong recovery of the AIDS business sector. However, GSK abandoned the tumor product Tafinlar+Mekinist and thrombocytopenic purpura drug Revolade/Promacta (Aiqu Popa) Under Novartis, they all became a $1 billion blockbuster.
With the rise of cancer immunotherapy products in 2015, GSK has begun to have a variety of calibre and will continue to express its focus on the oncology business. Emma Walmsley, who was promoted to CEO from the consumer health business, took office in March 2016. I started to re-adjust GSK's business structure, announced that some of the early R&D projects were cut to improve R&D efficiency, and 80% of R&D funding was concentrated on AIDS. Respiratory, tumor, autoimmune inflammatory diseases, this is GSK is determined to return to the field of cancer.
Since then, GSK has re-started the development of the oncology business through external cooperation, including the signing of a cell and gene therapy drug development contract with Mitenyi Biotech in March 2016 to jointly study the undeveloped CAR-T tumor target; in April 2016 with Zymeworks cooperates to develop bispecific antibodies, etc. From the official website, we can find two phase II projects in GSK's current tumor pipeline, including TCR-T cell therapy, antibody-conjugated drugs targeting BCMA, and six Phase I projects, including BET. OX40.TLR4. PI3K and other targets.
GSK announced in December 2018 that the acquisition of Tesaro for $5.1 billion is equivalent to a sense of presence in the tumor circle, as well as a project for PARP. PD-1 and a space to explore various combinations of tumor immunotherapy. The day before yesterday, GSK also signed an intensive 3.7 billion euro contract with Meck24, a dual-function protein drug in Germany (see: Merck/GSK to establish a global cooperation alliance, signed a 3.7 billion euro upgrade PD-1 development agreement), It is also another action of GSK's forward-looking and comprehensive layout of the tumor field.
At the company's overall strategic level, in order to focus on the pharmaceutical business and vaccine business including cancer, Emma Walmsley also launched a major operation on the consumer health business, first in March 2018 to repurchase the consumption held by Novartis for $13 billion. A 36.5% share of the health care joint venture company, and then an agreement with Pfizer in December 2018, the two sides separated their respective consumer health business, set up a new joint venture, globally independent in the name of GSK Consumer Healthcare Operating, GSK holds a 68% stake and plans to list in the UK within three years. The transaction is scheduled to be completed in the second half of 2019, when GSK's business focus will also focus on prescription drugs and vaccines.